Kamada To Discontinue Phase 3 InnovAATe Trial As Prespecified Interim Futility Analysis Shows The Trial Of Inhaled AAT For Alpha-1 Antitrypsin Deficiency Is Unlikely To Demonstrate A Statistically Significant Benefit In Its Primary Endpoint

Benzinga·12/08/2025 12:06:24

語音播報

Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint
Kamada Continues to Supply GLASSIA, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDA
Kamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million
Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026
Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term Growth